Xeris Pharmaceuticals

Real-time Quotes | Nasdaq Last Sale

Opening 10:53 12/02 EST
Corp Actions
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on November 25, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 18,000 shares, and restricted stock units for an aggregate of 70,200 shares, of its common stock to 11 new employee(s) under Xeris’ Inducement Equity Plan.
Business Wire · 4d ago
Earnings Release: Here's Why Analysts Cut Their Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Price Target To US$11.00
Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) just released its third-quarter report and things are looking bullish. Sales...
Simply Wall St. · 11/12 13:17
SNAP, NKLA, PINS and ERIC among premarket gainers
Astrotech Corporation (ASTC) +145% in reaction to its partnership with Cleveland Clinic.Marin Software (MRIN) +138%.NetSol Technologies (NTWK) +67% after its platform goes live in China.VOC Energy Trust (VOC) +27%.Greenpro Capital (GRNQ) +13%.Snap (SNAP) +22% on Q3
Seekingalpha · 10/21 12:21
The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20)
Benzinga · 10/21 12:04
Xeris Wins FDA Fast Track Path For Epilepsy Treatment; Shares Spike 9%
Shares in Xeris Pharmaceuticals are rising 9% in Wednesday's pre-market session after the company announced that the US Food and Drug Administration (FDA) granted Fast Track designation for its XP-0863 injection used in the treatment of acute repetitive seizures.Xeris (XERS) said that the complete results of the Phase 1b study were shared with the FDA. The US regulator provided feedback that Xeris’ drug development program for XP-0863 could advance directly into a Phase 3 registration study in both pediatric and adult patients with epilepsy.There are over 2.7 million people with epilepsy in the US with about 200,000 new patients diagnosed each year. About 30% and 40% of these patients are uncontrolled on oral therapy and are at risk for acute breakthrough seizures.“The FDA's Fast Track designation highlights the clear unmet need in treating acute repetitive seizures with the preparations of diazepam available today and highlights our opportunity to dramatically improve care through the introduction of a ready-to-use injection formulation," said Xeris CEO Paul R. Edick. "We are working to identify the right development and commercialization partner who can accelerate our efforts to evaluate and deliver this simple format that could make all the difference in an urgent seizure setting."XP-0863 was previously granted orphan designations both for the treatment of acute repetitive seizures and for the treatment of Dravet Syndrome.Xeris’ lead product, Gvoke, is a ready-to-use glucagon product for diabetic patients experiencing severe hypoglycemia, which has been approved as a prefilled syringe (PFS) and autoinjector (HypoPen). The HypoPen was launched on July 1, making it the first ready-to-use glucagon in a premixed autoinjector, with no visible needle. Hedge fund tycoon and billionaire George Soros has a 5.3% stake in the company.Piper Sandler analyst David Amsellem recently reiterated a Buy rating on the stock with a $11 price target following favorable feedback from a physician survey to gauge perceptions of Xeris’ Gvoke."The feedback, on the whole, points to significant growth in the footprint of Gvoke, particularly in the context of a glucagon rescue space that historically has been vastly underpenetrated,” Amsellem wrote in a note to investors. “We continue to believe that peak US sales for the Gvoke franchise of $250M+ are realistic, with upside to the extent that label expansion opportunities bear fruit (e.g., post-bariatric surgery patients).”“This translates into an attractive risk/reward profile at a market cap of under $300M," the analyst summed up. (See XERS stock analysis on TipRanks).Overall, the stock boasts a Strong Buy Street consensus, with 4 recent Buy ratings. With shares down 26% this year, the $12 average analyst price target implies a promising 129% upside potential.Related News: AbbVie Submits US, EU Rinvoq Applications For Atopic Dermatitis Pfizer Targets FDA Approval For Covid-19 Vaccine In November; Shares Rise Merck Nabs Expanded Keytruda Label For Hodgkin Lymphoma More recent articles from Smarter Analyst: * Telia Inks 5G Network Deals With Ericsson, Nokia * Prologis' 2020 Outlook Tops Estimates; Street Says Buy * Iberdrola’s Avangrid In $8.3B Renewable Energy Merger With PNM * Opko Health Rolls Out Multiplex COVID-19, Influenza A/B Test
SmarterAnalyst · 10/21 10:30
16 Stocks Moving In Wednesday's After-Hours Session
Gainers Astrotech (NASDAQ: ASTC) shares are trading higher after the company announced it partnered with The Cleveland Clinic to develop a rapid COVID-19 breath test.
Benzinga · 10/20 21:49
Xeris Pharma's XP-0863 Fast Track'd in U.S. for repetitive seizures
The FDA has designated Xeris Pharmaceuticals's (XERS) XP-0863 (diazepam non-aqueous injection) for fast track review for the treatment of acute repetitive seizures.XP-0863 was previously granted orphan designations both for the
Seekingalpha · 10/20 20:19
Xeris Pharmaceuticals Granted Fast Track Designation By The FDA For Its Novel Injectable Concentrated Diazepam Formulation (XP-0863) For Seizure Treatment
Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today
Benzinga · 10/20 20:07
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XERS. Analyze the recent business situations of Xeris Pharmaceuticals through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XERS stock price target is 11.00 with a high estimate of 14.00 and a low estimate of 7.00.
Institutional Holdings
Institutions: 127
Institutional Holdings: 26.56M
% Owned: 54.23%
Shares Outstanding: 48.98M
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Biotechnology & Medical Research
Pharmaceuticals & Medical Research
Key Executives
Chairman/Chief Executive Officer/Director
Paul Edick
Chairman/President/Chief Executive Officer/Director
paul Edick
President/Chief Operating Officer
John Shannon
Co-Founder/Chief Scientific Officer
Steven Prestrelski
Chief Financial Officer
Barry Deutsch
Senior Vice President/General Counsel/Secretary
Beth Hecht
Senior Vice President
Kenneth Johnson
Lead Director/Independent Director
John Schmid
Independent Director
BJ Bormann
Independent Director
Dawn Halkuff
Independent Director
Marla Persky
Independent Director
Jeffrey Sherman
Independent Director
Mark Thierer
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About XERS
Xeris Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing injectable and infusible drug formulations. It uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products. Its formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of formulations of peptides, proteins, antibodies and small molecules using commercially-available syringes, auto-injectors, multi-dose pens and infusion pumps. The Company is developing its lead product candidate, the Glucagon Rescue Pen, for the treatment of severe hypoglycemia in people with diabetes. It is also developing treatments for post-bariatric hypoglycemia, congenital hyperinsulinism, hypoglycemia-associated autonomic failure and exercise-induced hypoglycemia. Its Glucagon Rescue Pen offers a stable glucagon that is designed to be administered subcutaneously in a simple two-step process.
Hot Stocks

Webull offers kinds of Xeris Pharmaceuticals Inc stock information, including NASDAQ:XERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XERS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XERS stock methods without spending real money on the virtual paper trading platform.